Domain range

Introducing the New Aalto Bio Recombinant Mayarovirus E2 Glycoprotein Domain A Reagents

What is the world’s next virus of concern

DUBLIN – May 11, 2022 – (Newswire.com)

Aalto Bio Reagents Ltd., www.aaltobioreagents.com one of the world’s leading developers of critical raw materials for the development of diagnostic tests, today announced the availability of its novel insect-expressed recombinant Mayaro virus (MAYV) glycoprotein E2, domain A (code DR 6481) , expanding its portfolio of emerging and endemic infectious tests. disease markers.

Mayaro fever is an infection transmitted to humans through the bites of infected mosquitoes. The virus was initially isolated in Trinidad and Tobago in 1954 and since then cases have been reported mainly in South America, Central America and the Caribbean, particularly in areas near tropical rainforests. MAYV usually circulates in sylvatic transmission cycles by the Hemagog spp. However, there are growing fears that it is being introduced into urban areas by the more sinister Aedes Egyptian. There is no licensed vaccine currently available, and symptoms of Mayaro fever present a nonspecific clinical picture similar to other arboviral diseases (such as dengue, chikungunya, and Zika), so often misdiagnosed can occur. Additionally, there is a lack of diagnostic testing in endemic regions, making it likely to be underreported.

Like other alphaviruses, the MAYV E1 and E2 glycoproteins form a heterodimer and represent the immunodominant region of the virus. E1 mediates fusion, while E2 interacts with the host receptor and facilitates virus entry into target cells through membrane fusion. It has been reported that antibodies against the E2 protein appear to be strongly neutralizing (1). For this reason, the E2 glycoprotein has attracted great interest as a target for manufacturers of diagnostic tests, as well as vaccine developers. Although the disease is self-limiting and usually lasts 3 to 5 days, it is very disabling arthralgia can persist for many months after signifying the importance of MAYV serology testing over current gold standard PCR testing.

“Aalto Bio Reagents remains available to help diagnostics manufacturers and vaccine developers around the world meet their emerging disease diagnostic testing requirements as new variants and diseases emerge around the world. We will continue to manufacture new critical materials, as we have done since the beginning of the global health crisis of COVID-19, by providing top-notch critical raw materials products. With the addition of our novel recombinant Mayaro Virus E2 Glycoprotein Domain A glycoprotein, we seek to strategically develop the critical raw materials needed to diagnose Mayaro virus before the disease spreads. If we have learned anything from the Zika outbreak in 2015-16 and the SARS-CoV-2 pandemic to date, preparation is key,” said Philip Noone, CEO of Aalto Bio.

About Aalto Bio Reagents

Founded in 1978, Aalto Bio Reagents is a leading developer and supplier of raw materials to the in vitro diagnostics industry and research laboratories worldwide. We serve the largest multinational companies in our industry with a wide range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in vitro diagnostic application.

Contact: Tel: +353-1-4900685 Email: [email protected]

References

  1. Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, et al. Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and exit. Cell (2015) 163:1095-107. doi:10.1016/j.cell.2015.10.050

press release department
by
Newswire.com

Primary source:

Introducing the New Aalto Bio Recombinant Mayarovirus E2 Glycoprotein Domain A Reagents